DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Foretinib is an investigational drug.
There have been 8 clinical trials for Foretinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2006.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are GlaxoSmithKline, NCIC Clinical Trials Group, and [disabled in preview].
Recent Clinical Trials for Foretinib
|A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer||GlaxoSmithKline||Phase 2|
|Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer||NCIC Clinical Trials Group||Phase 1/Phase 2|
|A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer||NCIC Clinical Trials Group||Phase 2|